U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. ZOLGENSMA
  1. Vaccines, Blood & Biologics

STN: 125694
Proper Name: onasemnogene abeparvovec-xioi
Trade Name: ZOLGENSMA
Manufacturer: Novartis Gene Therapies, Inc.
Indication:

  • For the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi allelic mutations in the survival motor neuron 1 (SMN1) gene.

Product Information

Supporting Documents

Back to Top